BioHarvest Sciences Inc. Trademarks Its Breakthrough Non-GMO Proven Platform Technology: "BIO-PLANT CELLicitation"

BioHarvest Sciences Inc. Trademarks Its Breakthrough Non-GMO Proven Platform Technology: "BIO-PLANT CELLicitation"

New name to reflect the Biotech power of combining plant cell growth with elicitation of specific molecules to produce unique compounds of high human utility value

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") has announced the new trademark for its proprietary non-GMO Biotech platform technology. The new name, "Bio-Plant CELLicitation™," replaces "BioFarming" and underscores the potential for the technology to be used in the botanical drugs space.

"The Bio-Plant CELLicitation™ proven platform technology allows us to address multiple market verticals with multiple products under different categories," said CEO Ilan Sobel. "The elicitation element allowing the creation of patentable compounds that can be produced economically and consistently with cleanliness and high sustainability credentials, enables BioHarvest to potentially impact the botanical drugs market in addition to growing its core base business."

The CEO added, "the term CELLicitation™ better reflects the combined actions of growing plant cells in industrial-scale bioreactors while eliciting specific molecules and/or structures in order to produce unique botanical compounds with high human utility value."

The power of the Bio-Plant CELLicitation™ platform can be summed up as follows:

  1. It enables economical and consistent production of commercial biomass of unique plant-based metabolites (such as polyphenols, antioxidants, cannabinoids, terpenes, psychoactive molecules, proteins and more) without the need to grow the plant itself. The production in the industrial scale proprietary Bioreactors is done in aseptic conditions guaranteeing the highest levels of cleanliness.
  1. The end-to-end manufacturing process defined by the CELLicitation™ technology requires low CapEx and has higher sustainability credentials than alternative technologies available for producing metabolites.
  1. The elicitation of certain molecules of interest, without performing any genetic modification, produces full-spectrum unique and patentable compositions. These could be availed to consumers as functional food, dietary supplements, medical food, and botanical drugs.
  1. It has been proven on multiple plants and fruits. For example, VINIA®, a patented compound now commercially available, is being successfully sold in Israel and the US. It contains a complex of polyphenols with a unique elicited Piceid Resveratrol at a factor of 100x. The product pipeline includes olive cells, which include a complex of polyphenols with Verbascoside at a 10x elicitation factor, and a Pomegranate-based product including PGG at a 5x elicitation factor.

  2. The Cannabis-based product based on the CELLicitation™ platform will contain unique patentable compositions of Cannabinoids and terpenes in trichomes, some of which have been elicited at various substantial factors.
  1. It removes the barriers hindering the successful development of botanical drugs. The patentability of the compounds, and the repeatability and consistency of production, increase the success odds for botanical drugs.
  1. It creates a wealth of intellectual property in the biology area: BHSC has 14 registered patents and 2 pending. More market verticals that can take advantage of CELLicitation™ will be announced throughout this year.

"Ever since we started the development of our platform technology, we knew it had more advantages than just growing the plant cells to produce the original compound of metabolites," said Dr. Yochi Hagay, co-founder and CTO. "The proven results of eliciting certain molecules and structures from the original plant not only justifies the new name of Bio-Plant CELLicitation™ but also creates the opportunity to produce innovative and patentable botanical compounds."

BioHarvest recently announced that it produced a significant amount of Cannabis biomass without growing the plant itself, using the Bio-Plant CELLicitation™ platform technology. The company plans to bring to market its first Cannabis-based products in 2022. BioHarvest has also announced that it expects revenues in 2022 to be USD 5-7M, representing a range of 2.5x-3.5x growth over 2021.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance that the Company sales revenue for 2022 will reach USD 5 to 7 million and there is no assurance of commercial availability of our Cannabis product in 2022. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/113965

News Provided by Newsfile via QuoteMedia

BHSC:CNX
The Conversation (0)
Life Sciences Virtual Investor Conference Agenda Announced for September 15th

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th .

Individual investors, institutional investors, advisors, and analysts are invited to attend this virtual event showcasing live executive presentations from companies addressing worldwide opportunities in the life sciences.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioHarvest Sciences to Webcast Live at VirtualInvestorConferences.com September 15th

BioHarvest Sciences to Webcast Live at VirtualInvestorConferences.com September 15th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE:8MV), a biotechnology company focused on growing plant cells without the plant via its patented CELLicitation platform, today announced that Ilan Sobel, Chief Executive Officer, will present live at VirtualInvestorConferences.com on September 15, 2022.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Business Intelligence Group Awards BioHarvest Sciences with the Prestigious Sustainability Leadership Award

Business Intelligence Group Awards BioHarvest Sciences with the Prestigious Sustainability Leadership Award

  • The award recognizes the sustainability impact of BioHarvest's Bio Plant CELLicitation technology, which enables industrial production of plant metabolites without growing the plant itself
  • BioHarvest Sciences receives the award with other industry thought leaders such as AstraZeneca, Agilent, and Honeywell

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6168/136029_b77540d5d49ee908_002.jpg

Figure 1

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/136029_b77540d5d49ee908_002full.jpg

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
BioHarvest Sciences Inc. Launches First Major United States Marketing Campaign

BioHarvest Sciences Inc. Launches First Major United States Marketing Campaign

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") has announced the first multimedia campaign for VINIA™ in the USA, Phase 1. The company is scaling up its US marketing in line with a 2022 growth plan that aims for significant growth in sales orders following commercial entry in 2021.

"We are delighted to launch our first integrated marketing campaign aimed at expanding our loyal customer base here in the USA," said CEO Ilan Sobel, in New York for the launch. "Bringing our new 20 Ton production facility online was integral to scaling global VINIA™ supply, so this marketing launch is testament to the entire VINIA™ team's coordinated dedication to making it happen."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
BioHarvest Sciences Inc. Commences Trading on the OTCQB Market

BioHarvest Sciences Inc. Commences Trading on the OTCQB Market

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") ") is pleased to announce that its common shares are now trading on the OTCQB® Venture Market under the ticker symbol "CNVCF".

"Admission to the OTCQB® market is an important step to increase US investor access to BioHarvest Sciences, and it provides US investors an additional level of transparency as we expand both our investor base and our customer base in North America." Stated CEO Ilan Sobel. "We will continue to work on expanding our global visibility to investors to match the commercial entry of our products into new markets."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×